
|Articles|September 1, 2004
- Volume 0 0
Incontinence Is Treatable
Advertisement
Surveys and studies have shown that stress urinary incontinence (SUI) can be frustrating, inconvenient, and even embarrassing for individuals with this condition. Risk factors for SUI include advancing age, childbirth, smoking, and obesity. While there are treatment options, experts said that the best treatment depends on the cause of incontinence and the individual's personal preference.
Health care professionals recommended the following options:
- Kegel exercises, depending on the severity of the condition. Kegel exercises strengthen the pelvic muscles involved in urination. These exercises involve briefly contracting and then releasing the muscles that control urinary flow. Kegel exercises have been shown to improve or cure urinary incontinence in most individuals who use them.
- Dietary changes, such as avoiding caffeine, nicotine, and spicy food.
- Surgery to add support for the bladder neck is usually recommended for severe stress incontinence that does not respond to medication or exercise.
Articles in this issue
almost 22 years ago
Fluoroquinolones: Focus on Safetyalmost 22 years ago
Computer Retrains Kids to Eat Properlyalmost 22 years ago
"Importation" of Prescription Drugsalmost 22 years ago
Courts Wrestle with Overtime Pay for Pharmacistsalmost 22 years ago
COMPOUNDING HOTLINEalmost 22 years ago
Clinical Update on the Treatment of Constipation in Adultsalmost 22 years ago
Texas Hospital Installs Omnicell Technologyalmost 22 years ago
Happy Harry's Installs Robotic Dispensing Systemsalmost 22 years ago
Medicare Recognizes Obesity as Illnessalmost 22 years ago
Gastric Bypass Causes Drop in Appetite StimulationAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Hidden Reimbursement Crisis in Medicare’s Drug Price Negotiation Program
2
FDA Grants Breakthrough Therapy Designation to Investigational Cannabis-Derived Therapy for Chronic Low Back Pain
3
ADA 2026: Optimized Inhaled Insulin Dosing Outperforms Subcutaneous Analogs for Postprandial Glucose in T1D
4
ADA 2026: Survodutide Cuts Visceral Fat and Normalizes Liver Fat in MASLD. Here's What the Data Mean for Metabolic Risk
5






































































































































